Clinical trials: Seizure Disorder
Epilepsy
Flexible Representation of Speech
The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane.
- Trial name
- NCT05209386
- Testing
- Dimension-Based Statistical Learning
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Pittsburgh
Catamenial Epilepsy
Fycompa in Catamenial Epilepsy
The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy.
- Trial name
- NCT05201703
- Testing
- Fycompa, Fycompa with a boost
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Epilepsy
Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ pharmacokinetics.
- Trial name
- NCT02284854
- Testing
- BIA 2-093, Carbamazepine
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Partial Seizures, Epilepsies, Partial
Once-A-Day Pregabalin For Partial Seizures
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs.
- Trial name
- NCT01262677
- Testing
- pregabalin
- Where
- 82 sites in United States, Argentina and 16 more
- Volunteers
- 325 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seizures
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion.
- Trial name
- NCT02324673
- Testing
- Cannabidiol Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- INSYS Therapeutics Inc
Brain Tumor Related Epilepsy (BTRE)
Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is effective in routine clinical practice for patients with epilepsy caused by a brain tumor.
- Trial name
- VIBES (NCT02276053)
- Where
- 24 sites in France, Germany and 4 more
- Volunteers
- 93 people
- Sponsor
- UCB BIOSCIENCES GmbH
Epilepsy, Seizures
University of Alabama at Birmingham (UAB) Pediatric CBD Program
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.
- Trial name
- NCT02695537
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Alabama at Birmingham
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or…
- Trial name
- NCT02279667
- Testing
- BIA 2-093
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine
Single centre, open-label, randomised study in four parallel groups of healthy volunteers
- Trial name
- NCT02281591
- Testing
- BIA 2-093, S-licarbazepine, R-licarbazepine
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
- Trial name
- BRITE™ (NCT01339559)
- Testing
- Brivaracetam
- Where
- 184 sites in United States, Austria and 26 more
- Volunteers
- 767 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Status Epilepticus
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
The purpose of this study is to determine the efficacy, safety and pharmacokinetics of Lorazepam on Japanese patients with Status Epilepticus or Repetitive Status Eplilepticus.
- Trial name
- NCT02239380
- Testing
- Lorazepam
- Where
- 20 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Pfizer
Seizure Disorders
A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.
Subjects will be asked to substitute their usual vitamin and mineral supplement/s with FruitiVits for seven consecutive days.
- Trial name
- FruitiVits (NCT02229318)
- Testing
- FruitiVits
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Vitaflo International, Ltd
Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration
- Trial name
- NCT01364558
- Testing
- Diazepam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Epilepsy, Sudden Cardiac Death
Optimization of VNS in Epileptic Patients to Induce Cardioprotection
This study is a non-randomized, prospective study in patients with a diagnosis of epilepsy and previously implanted FDA approved Vagus Nerve Stimulation (VNS) devices.
- Trial name
- NCT04387435
- Testing
- A change or titration in the current or frequency settings of the VNS therapy system.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Los Angeles
Epilepsy
RNS® System LTT Study
The RNS® System LTT study is designed to assess the ongoing safety and to evaluate the long-term efficacy of the RNS® System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older…
- Trial name
- NCT00572195
- Testing
- RNS® System
- Where
- 33 sites in United States
- Volunteers
- 230 people
- Sponsor
- NeuroPace
15q Duplication Syndrome, CDKL5 Deficiency Disease
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
- Trial name
- NCT03694275
- Testing
- Soticlestat
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Takeda
Epilepsy
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.
- Trial name
- NCT00938912
- Testing
- Lacosamide
- Where
- 69 sites in United States, Belgium and 9 more
- Volunteers
- 366 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
This is a two-arm, randomized, double-blind, non-inferiority study using a flexible dosing regime to allow optimal zonisamide or carbamazepine therapy for individual subjects.
- Trial name
- NCT00477295
- Testing
- Zonisamide, Carbamazepine
- Where
- 79 sites in Australia, Denmark and 16 more
- Volunteers
- 583 people
- Sponsor
- Eisai Inc.
Seizures
Dosing of Levetiracetam (Keppra) in Neonates
The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with seizures.
- Trial name
- NCT01239212
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati